Fennec Pharmaceuticals collaborates with Tampa General Hospital on cisplatin ototoxicity study.

Fennec Pharmaceuticals has announced a clinical research collaboration with Tampa General Hospital Cancer Institute to evaluate the real-world clinical utility of sodium thiosulfate injection (PEDMARK) in reducing ototoxicity in adolescent and young adult patients with non-metastatic solid tumors receiving cisplatin chemotherapy. The study aims to assess the effectiveness of PEDMARK in a real-world setting, providing valuable insights into its clinical utility.